Pleuromutilin Antibacterial Drug Class List

Drugs in Drug Class: Pleuromutilin Antibacterial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes	8,153,689		Y	Y
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes	8,071,643		Y	Y
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes	8,153,689		Y	Y
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes	9,120,727		Y	Y
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes

Market Dynamics and Patent Landscape for Pleuromutilin Antibacterial Drugs

Last updated: April 25, 2026

Where does the pleuromutilin antibacterial market sit today?

Pleuromutilin antibacterials are a small but commercially meaningful subsegment of the veterinary and human antibacterial landscape, driven by (1) distinct mechanisms and (2) formulation opportunities in companion and animal health. Commercial exposure is concentrated in a narrow set of marketed actives, with most late-stage innovation aimed at new indications, improved exposure, and targeted development rather than broad label expansion.

Market structure (practical read-through for investors)

• Human antibacterial footprint: Limited active options globally compared with beta-lactams, macrolides, and fluoroquinolones. Pleuromutilins are used where regulatory pathways and stewardship considerations align with unmet needs.
• Veterinary share: Veterinary use is the dominant commercialization pathway historically, tied to respiratory disease management and optimized pharmacokinetics.
• Competitive set: Competes indirectly via respiratory and Gram-positive coverage claims with macrolides, lincosamides, and tetracyclines; pleuromutilin differentiation is typically framed around resistance profiles and dosing convenience.

Demand drivers

• Respiratory indications remain the core commercial thesis (especially in animals), because disease is common and outcomes depend on exposure-time relationships.
• Resistance pressure supports stewardship positioning where pleuromutilins maintain activity against specific resistant phenotypes.
• Dosing and formulation drive uptake: improvements that reduce dosing frequency or improve therapeutic index support veterinary procurement decisions.

Which pleuromutilin antibacterials anchor the landscape?

The commercial backbone of this class is centered on three actives: tiamulin, retapamulin (pleuromutilin derivative), and tulathromycin/tildipirosin are not pleuromutilins (often confused in industry discussions), so the actionable anchor here is the pleuromutilin-specific set.

Market-relevant pleuromutilin antibacterials (anchor compounds)

Active	Class position	Typical commercialization focus	Competitive role
Tiamulin	Pleuromutilin antibacterial	Veterinary respiratory and enteric disease	Core market earner; generics and reformulations define later-cycle competition
Retapamulin	Pleuromutilin derivative	Topical skin antibacterial development in humans	Differentiation hinges on localized exposure and resistant-pathogen coverage
Other pleuromutilin derivatives	Derivatives with modified side chains	Mostly pipeline, sometimes veterinary	Gene-to-label strategy: exposure, resistance coverage, and regimen design

Key market dynamic: Once an active loses exclusivity, the commercial battle shifts from “molecule performance” to formulation, method-of-use exclusivity, and IP around polymorphs, salts, and dosing regimens, not to new microbiology claims alone.

How does the patent landscape map to value drivers?

Pleuromutilin antibacterials typically generate IP packages that bifurcate into:

1. Composition-of-matter (new pleuromutilin derivatives, salts, polymorphs).
2. Formulation and delivery (topical gels/creams, veterinary premixes, particle engineering).
3. Methods of use (indications, dosing regimens, patient population definitions).
4. Manufacturing/process IP (synthesis routes, crystallization conditions, impurity controls).

IP value chain for the class

Value driver	What patents claim	Why it matters in exclusivity and litigation
Derivative chemistry	New side chains or scaffold modifications	Defines the first exclusivity layer; often expires first among hard IP
Polymorph/salt forms	Crystalline forms, amorphous forms, hydrates/solvates	Can extend exclusivity when supported by robust characterization and stability data
Topical/veterinary formulations	Vehicle choice, excipient systems, particle sizes, viscosity windows	Practical barriers for generics and “at-risk” product launch
Dosing regimens	mg/kg schedules, frequency, duration, feed or administration sequence	Method-of-use is often the last enforceable layer in many animal programs
Manufacturing processes	Specific reaction conditions and purification steps	Hardens barriers against “workalike” production

What do major regulatory and exclusivity frameworks imply for pleuromutilins?

The class plays out across human and veterinary regulatory systems, but the exclusivity logic is consistent:

• Human: composition and method-of-use patents can be followed by regulatory exclusivities (where available) and pediatric/indication extensions depending on jurisdiction.
• Veterinary: exclusivity frequently relies more heavily on data protection and method claims than on broad patent-term management, with competition emerging through reformulation and generic routes.

Which pleuromutilin IP themes dominate filings?

Across pleuromutilin antibacterial portfolios, the dominant patent themes follow predictable patterns:

Chemistry

• new pleuromutilin core derivatives
• modified side chains to tune spectrum and exposure
• salt forms and crystalline forms that improve stability

Product engineering

• topical formulations with defined rheology and spreadability
• veterinary dosage forms designed for mixing stability and predictable bioavailability

Clinical/regimen differentiation

• dosing frequency windows
• duration-of-therapy definitions linked to specific indications

Where are the patent risks for market entry (and generic challenge)?

For pleuromutilin antibacterials, the key entry risks are not only whether a competitor can design around the active scaffold, but whether the competitor can avoid downstream IP on:

• specific polymorphs and stability-tested solid-state forms
• formulation compositions tied to critical quality attributes
• label-protected dosing regimens and patient/animal population definitions
• process impurities and manufacturing constraints that are claimed in process patents

In practice, generic challengers often accept composition design-around but lose time or exclusivity to formulation- and regimen-level patents.

What are the litigation and challenge dynamics in this class?

Litigation behavior in pleuromutilins aligns with broader antibacterial patterns:

• first wave: disputes over derivative validity and scope
• second wave: disputes over formulation and solid-state design-around
• third wave: disputes over method-of-use and regimen infringement tied to label-driven prescribing

This matters commercially because even after composition-of-matter invalidity arguments fail, companies still face delay if they cannot secure clean launch pathways due to formulation or dosing IP.

How do you underwrite the pipeline and investment outlook?

A practical underwriting approach for the pleuromutilin antibacterial class is to separate:

• Active discovery risk (derivative chemistry and microbiology) from
• Regulatory and commercialization risk (formulation performance and label differentiation) and then map each portfolio to the last enforceable patent layer.

Investment-ready underwriting checklist (class-specific)

• Does the portfolio protect one enforceable layer or does it stack chemistry + polymorph + formulation + regimen?
• Are solid-state claims supported by strong characterization that downstream competitors cannot easily replicate?
• Is the marketed or proposed regimen tight enough to support enforcement risk for a generic challenger?

What is the near-term market dynamic as patents age?

As dominant actives age, the market typically shifts to:

• generics and “me-too” formulation improvements
• label consolidation by regulators
• competitive differentiation through dosing convenience rather than novel pharmacology

For pleuromutilins, this shift is amplified by how often dosing and formulation define performance in the field (especially veterinary respiratory care).

Key Takeaways

• Pleuromutilin antibacterials are a niche antibacterial class with commercialization concentrated in a small set of actives, anchored by tiamulin (historically veterinary) and retapamulin (notably topical human development).
• The patent landscape is structurally layered: derivative chemistry, solid-state forms, formulation and delivery, and methods of use/regimens.
• Market entry risk for competitors typically concentrates on polymorph/salt design-around, formulation composition, and label-linked dosing regimens, not only on avoiding the core scaffold.
• As exclusivity ages, competition shifts toward formulation and regimen, which means the last enforceable IP layer often determines practical launch timing more than first-in-class microbiology claims.

FAQs

1) What patent types most extend exclusivity in pleuromutilin antibacterial portfolios?

Polymorph/salt patents, formulation patents (especially topical or veterinary vehicle and critical quality attributes), and method-of-use or regimen patents.

2) Why do dosing regimens matter so much for generic entry in this class?

Because infringement analysis often ties to label-defined administration timing and duration, and competitors can be blocked even when the active scaffold is design-around successful.

3) Where are the highest defensible barriers: chemistry or formulation?

Typically both, but the most repeatable barriers for practical launch delay are formulation and solid-state IP, because they are harder to replicate without prior art and robust characterization.

4) Is the pleuromutilin market more human or veterinary?

The commercial footprint is historically stronger in veterinary, while human activity is concentrated in fewer development programs, often in topical or specific localized indications.

5) How should diligence teams prioritize sources for freedom-to-operate in pleuromutilins?

Focus on patent families covering the marketed formulation, solid-state forms, and regimen claims, not only composition-of-matter.

References

[1] European Medicines Agency (EMA). (n.d.). Human and veterinary medicinal products: regulatory and procedural information. EMA. https://www.ema.europa.eu/
[2] US FDA. (n.d.). Drugs and biologics: regulatory information and approval pathways. U.S. Food and Drug Administration. https://www.fda.gov/drugs
[3] European Patent Office (EPO). (n.d.). EPO patent search and classification resources. European Patent Office. https://www.epo.org/searching-for-patents.html
[4] WIPO. (n.d.). Patent information resources and search tools. World Intellectual Property Organization. https://www.wipo.int/patents/en/